Ottawa-Shanghai Joint School of Medicine


HE Min


Tel: 13917019110


postgraduate and served as an Deputy chief physician. Youth committee member of both the pancreatic surgery branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) and the Biliary tumor major of Shanghai Anticancer Association. In clinical practise,I am mainly engaged in the basic and clinical study on the Hepato-Biliary-Pancreatic surgery and the abdominal hernia surgery, I am good at different kind of minimally invasive operations in the field of Hepato-Biliary- Pancreatic and abdominal hernia which are included the laparoscopic distal pancreatectomy, laparoscopic splenectomy, single port laparoscopic cholecystectomy, laparoscopic common bile duct exploration, laparoscopic repair of inguinal hernia, hernioplasty for Incisional Hernia and so on, and  have profound attainments in the field of hepato-Biliary-Pancreatic minimally invasive surgery. In scientific research, I have conducted in comprehensively and deeply studies on the Biliary tumor immunotherapy area and Precision treatment area, and gained funds which come from the Medical-Engineering Crossed Fund of Shanghai Jiao Tong University and the Clinical research innovation cultivating fund of Ren Ji Hospital affiliated to Shanghai Jiao Tong University. I am also participated in several national and municipal multi-center clinical studies which included the project supported by National Science and Technology Ministry(sub-subject): Construction and evidence-based evaluation of precision hepatobiliary surgical technique system. And the project of  Shanghai science and technology commission: the perihilar precision surgical technique system in biliary tract surgery can promote the safety and efficacy of hepatobiliary tumor surgery, and the project of Hospital Development Center:  Genome-based drug screening model to treat Biliary tract cancer. I am equipped with rich experience in clinical and basic research. During my working experience, I published 10 papers in core journals at both home and abroad as first author or the joint first authors which were included 3 SCI papers. I also participated in redact many treatise like: Clinical surgery of the duodenal region of bile duct, Shi Weijin Biliary surgery, Surgical atlas of biliary tract and biliary pancreaticoduodenal region, Surgical procedure diagnosis and so on. In teaching experience, I participate in teaching the biliary pancreatic disease and inguinal hernia for undergraduate  seven-year-postgraduate and eight- year-postgraduate student for both noviciate and internship student. I also engaged in the Problem-Based Learning (PBL) and was given the title of “ Hospital Excellent teacher ”

Study experience

  • 2000/09-2007/07, Shanghai JiaoTong University, clinical medicine study for 7 years in medical college, postgraduate, tutor: Jian Wang.

  • 2007/07-2013/10, Renji hospital affiliated to Shanghai JiaoTong University medical school general surgery department, resident doctor.

  • 2013/11-untill now, Renji hospital affiliated to Shanghai JiaoTong University medical school, attending doctor.

Representative treatise

  1. Min He,Ming Zhan,Wei Chen,et al.MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1α in Gallbladder Cancer.Cell Physiol Biochem 2017;42:2078-2092

  2. Min He,Ying Wang,Wei Jin Shi,et al.Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.Journal of Digestive Diseases,2011; 12; 393-400.

  3. Liang Liu*, Hua-Xiang Xu*, Min He*, Novel Score System Predicts Postsurgical Survival and Adjuvant Chemotherapeutic Benefits in Patients with Pancreatic Adenocarcinoma:Should Biologic Markers be Included in AJCC-TNM Staging System? Surgery.2018.

  4. Wang J,He M,Shi W,et al.Inducible costimulator(ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.Cancer Invest.2009;27(3):244-250.

  5. He min,Wang Haolu,Yan Jiayan,et al.The safety and effect of Transhepatic Hilar Approach for the treatment of Bismuth Types III and IV HilarCholangiocarcinoma.Chin J Surg,2018;56(5):359-365

  6. He Min,Wang Jian.The Method and effect of the Preoperative resection of hilar cholangiocarcinoma.J Clin Surg,2017(6):419-422

  7. He Min,Yan Jiayan,Chen wei,et al.Surgical therapy of biliary restenosis after repair for bile duct injury in 16 cases.Chin J Gen Surg,2017(8):672-676

  8. He Min,Wang Jian.The Diagnostic Strategy of cholangio-pancreatic duct dilatation with unknown cause.J Hepatopancreatobiliary Surg,2017;29(3):177-180.

  9. He Min,Wang Jian Chen Tao.Diagnosis and treatment of xanthogranulomatous cholecystitis.Chin J Hepatobiliary Surg,2013;19(3):232-233

  10. He Min,Shi Yuqian Wang Jian.Expression of hypoxia-inducible factor-1a,vascular endothelialgrowth factor and its receptors in pancreatic cancer and prognosis of patients.Shanghai Med J,2012;35(11):924-926

  11. He Min,Wang Jian Shi Yuqian,et al.Selection of surgical procedures for cholangiocarcinoma and the corresponding prognosis.Chin J Dig Surg,2008;7(4):277-280

  12. He Min,Wang Jian.Diagnosis and treatment of xanthogranulomatous cholecystitis.Chin J Hepatobiliary Surg.2007;13(8):566-567

  13. He Min,Wang Jian,Shi weijin.Progress in surgical treatment of chronic pancreatitis.J Hepatopancreatobiliary Surg,2006;18(5):329-331

  14. He Min,Chen Tao,Wang Jian.Sarcomatoid carcinoma of the body and tail of the pancreas: a case report.Chin J Gen Surg.2006;21(9):646

Undertake projects

  • Supported by the medical-Engineering Crossed Fund of Shanghai JiaoTong University:An improved laparoscopic sleeve system with fixed hemostatic suture. Fixed number of years of the study:2016.1-2018.12. Fund: 120 thousand RMB, under research

  • Supported by the Clinical research innovation cultivating funding plan of Ren Ji Hospital affiliated to Shanghai Jiao Tong University:  The establishment of xenograft model of human - derived mice in biliary tumors and the clinical control study on the efficacy of individual precision chemotherapy. Fixed number of years of the study: 2018.1-2020.12. Fund: 100 thousand RMB, under research.